Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RDHL | RedHill Biopharma Ltd.

Index- P/E- EPS (ttm)-4.18 Insider Own4.37% Shs Outstand5.85M Perf Week-0.84%
Market Cap4.63M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.93M Perf Month-15.57%
Income11.60M PEG- EPS next Q- Inst Own7.30% Short Float / Ratio0.26% / 0.02 Perf Quarter-54.11%
Sales35.70M P/S0.13 EPS this Y44.90% Inst Trans-76.09% Short Interest0.01M Perf Half Y-85.69%
Book/sh0.90 P/B0.89 EPS next Y- ROA11.30% Target Price- Perf Year-97.03%
Cash/sh1.22 P/C0.66 EPS next 5Y- ROE-52.00% 52W Range0.76 - 38.40 Perf YTD-85.69%
Dividend- P/FCF- EPS past 5Y14.80% ROI-57.70% 52W High-97.91% Beta2.01
Dividend %- Quick Ratio0.80 Sales past 5Y72.80% Gross Margin42.70% 52W Low5.66% ATR0.08
Employees113 Current Ratio1.00 Sales Q/Q-90.20% Oper. Margin21.50% RSI (14)35.19 Volatility12.76% 7.57%
OptionableNo Debt/Eq0.66 EPS Q/Q102.40% Profit Margin32.40% Rel Volume0.82 Prev Close0.80
ShortableYes LT Debt/Eq0.29 EarningsJun 12 BMO Payout- Avg Volume388.55K Price0.80
Recom2.00 SMA20-8.47% SMA50-26.33% SMA200-80.82% Volume318,913 Change0.35%
Date Action Analyst Rating Change Price Target Change
Aug-31-21Initiated Cantor Fitzgerald Overweight $22
May-18-21Initiated H.C. Wainwright Buy $23
Sep-11-20Initiated BTIG Research Buy
Jul-12-19Upgrade WBB Securities Buy → Strong Buy
Mar-12-19Upgrade WBB Securities Speculative Buy → Buy
Jan-26-18Initiated Nomura Buy $18
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Jun-15-15Reiterated ROTH Capital Buy $27.50 → $30
Sep-18-23 07:00AM
Sep-05-23 07:00AM
Aug-17-23 07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
03:58PM Loading…
Jul-25-23 03:58PM
Jul-21-23 09:33AM
Jun-12-23 08:00AM
May-22-23 07:00AM
May-15-23 06:17PM
May-09-23 07:00AM
May-01-23 07:00AM
Apr-28-23 07:00AM
Apr-17-23 07:39AM
07:00AM Loading…
Apr-11-23 07:00AM
Apr-03-23 01:26PM
Mar-30-23 08:00AM
Mar-23-23 07:32AM
Mar-21-23 07:00AM
Mar-16-23 06:15PM
Mar-08-23 07:05PM
Feb-28-23 08:01AM
Feb-16-23 08:01AM
Feb-15-23 07:00AM
Feb-10-23 03:10PM
Feb-06-23 07:00AM
Jan-26-23 07:00AM
11:07AM Loading…
Jan-03-23 11:07AM
Dec-27-22 02:53PM
Dec-07-22 09:45AM
Dec-06-22 01:36PM
Dec-02-22 09:00AM
Dec-01-22 04:01PM
Nov-29-22 08:00AM
Nov-24-22 05:19AM
Nov-17-22 08:30AM
Nov-15-22 03:09PM
Nov-14-22 08:59AM
Nov-13-22 07:33AM
Nov-07-22 09:49AM
Nov-04-22 07:00AM
Oct-30-22 08:58AM
Oct-27-22 07:45AM
Oct-26-22 07:00AM
Oct-20-22 01:08PM
Oct-19-22 12:34PM
Oct-18-22 07:00AM
Oct-03-22 11:20AM
Aug-18-22 11:04AM
Aug-17-22 10:12AM
Aug-10-22 08:17AM
Jul-12-22 08:00AM
Jun-24-22 05:31AM
Jun-23-22 01:01PM
Jun-17-22 08:30AM
May-25-22 09:15AM
May-10-22 07:37AM
May-09-22 08:30AM
May-06-22 11:20AM
May-04-22 03:17PM
Apr-14-22 09:55AM
Apr-11-22 09:00AM
Mar-17-22 07:59AM
Mar-15-22 09:00AM
Mar-10-22 07:00AM
Mar-03-22 04:10AM
Mar-02-22 04:18PM
Mar-01-22 12:00PM
Feb-17-22 09:30AM
Feb-07-22 01:38PM
Jan-18-22 01:38PM
Jan-13-22 11:51AM
Jan-06-22 09:15AM
Dec-20-21 08:35AM
Dec-15-21 09:16AM
Dec-14-21 08:35AM
Dec-09-21 01:05PM
Dec-08-21 10:58AM
Dec-06-21 07:01AM
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.